pick bodies
Recently Published Documents


TOTAL DOCUMENTS

62
(FIVE YEARS 0)

H-INDEX

17
(FIVE YEARS 0)

2019 ◽  
Vol 10 (1) ◽  
pp. 7 ◽  
Author(s):  
Masanori Kurihara ◽  
Tatsuo Mano ◽  
Yuko Saito ◽  
Shigeo Murayama ◽  
Tatsushi Toda ◽  
...  

The mechanism of neuronal dysfunction via tau aggregation in tauopathy patients is controversial. In Alzheimer’s disease (AD), we previously reported mislocalization of the DNA repair nuclear protein BRCA1, its coaggregation with tau, and the possible importance of the subsequent DNA repair dysfunction. However, whether this dysfunction in BRCA1 also occurs in other tauopathies is unknown. The aim of this study was to evaluate whether BRCA1 colocalizes with tau aggregates in the cytoplasm in the brains of the patients with tauopathy. We evaluated four AD, two Pick’s disease (PiD), three progressive supranuclear palsy (PSP), three corticobasal degeneration (CBD), four normal control, and four disease control autopsy brains. Immunohistochemistry was performed using antibodies against BRCA1 and phosphorylated tau (AT8). Colocalization was confirmed by immunofluorescence double staining. Colocalization of BRCA1 with tau aggregates was observed in neurofibrillary tangles and neuropil threads in AD, pick bodies in PiD, and globose neurofibrillary tangles and glial coiled bodies in PSP. However, only partial colocalization was observed in tuft-shaped astrocytes in PSP, and no colocalization was observed in CBD. Mislocalization of BRCA1 was not observed in disease controls. BRCA1 was mislocalized to the cytoplasm and colocalized with tau aggregates in not only AD but also in PiD and PSP. Mislocalization of BRCA1 by tau aggregates may be involved in the pathogenesis of PiD and PSP.


Author(s):  
Masataka Nakamura ◽  
Satoshi Kaneko ◽  
Dennis W Dickson ◽  
Hirofumi Kusaka

Abstract BRCA1 plays an important roles in several biological events during the DNA damage response (DDR). Recently, some reports have indicated that BRCA1 dysfunction is involved in the pathogenesis of Alzheimer disease (AD). Furthermore, it has also been reported that BRCA1 accumulates within neurofibrillary tangles (NFTs) in the AD brain. In this study, we examined the immunohistochemical distribution of BRCA1 and another DDR protein, p53-Binding Protein 1 (53BP1), in AD, Pick disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration, and frontotemporal dementia with parkinsonism linked to chromosome 17. In control subjects, neither BRCA1 nor phosphorylated BRCA1 (pBRCA1; Ser1524) immunoreactivity was observed in neurons or glial cells; and that for pBRCA1 (Ser1423) and 53BP1 were slightly detected in neuronal nuclei. The immunoreactivity for both BRCA1 and pBRCA1 (Ser1423) was localized within phosphorylated tau inclusions in all tauopathies, whereas that for pBRCA1 (Ser1524) was mainly associated with Pick bodies in PiD and to a lesser extent with NFTs in AD. On the other hand, 53BP1-immunoreactive deposits tended to be increased in the nucleus of neurons in AD and PSP compared with those in control cases. Our results suggest that DDR dysfunction due to cytoplasmic sequestration of BRCA1 could be involved in the pathogenesis of tauopathies.


2019 ◽  
Vol 30 (5) ◽  
pp. 555-572 ◽  
Author(s):  
Elnaz Amanzadeh ◽  
Abolghasem Esmaeili ◽  
Soheila Rahgozar ◽  
Maryam Nourbakhshnia

Abstract Quercetin is a polyphenolic flavonoid, which is frequently found in fruits and vegetables. The antioxidant potential of quercetin has been studied from subcellular compartments, that is, mitochondria to tissue levels in the brain. The neurodegeneration process initiates alongside aging of the neurons. It appears in different parts of the brain as Aβ plaques, neurofibrillary tangles, Lewy bodies, Pick bodies, and others, which leads to Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and other diseases. So far, no specific treatment has been identified for these diseases. Despite common treatments that help to prevent the development of disease, the condition of patients with progressive neurodegenerative diseases usually do not completely improve. Currently, the use of flavonoids, especially quercetin for the treatment of neurodegenerative diseases, has been expanded in animal models. It has also been used to treat animal models of neurodegenerative diseases. In addition, improvements in behavioral levels, as well as in cellular and molecular levels, decreased activity of antioxidant and apoptotic proteins, and increased levels of antiapoptotic proteins have been observed. Low bioavailability of quercetin has also led researchers to construct various quercetin-involved nanoparticles. The treatment of animal models of neurodegeneration using quercetin-involved nanoparticles has shown that improvements are observed in shorter periods and with use of lower concentrations. Indeed, intranasal administration of quercetin-involved nanoparticles, constructing superparamagnetic nanoparticles, and combinational treatment using nanoparticles such as quercetin and other drugs are suggested for future studies.


2019 ◽  
Vol 78 (10) ◽  
pp. 971-974
Author(s):  
Keitaro Okada ◽  
Yukiko Hata ◽  
Yoichiro Takayanagi ◽  
Tsutomu Takahashi ◽  
Isao Takayanagi ◽  
...  

Abstract Here, we report a 74-year-old woman with a long history of schizophrenia but no clinical manifestation of dementia. Cause of death after autopsy was atherosclerotic heart disease. Although neuropathological investigation showed no significant brain atrophy, superficial microvacuolation with neuronal loss was restrictedly detected in the right anterior cingulate gyrus by microscopic examination. Pick bodies (PBs) positive for Bodian and Bielshowsky staining and 3-repeat-tau were detected in frontal and temporal lobes and limbic regions. Prevalence of PBs was most frequent in the right anterior cingulate gyrus and lateral base, followed by other neocortical regions of the frontal lobe, amygdala, and granular layer of the hippocampus. Although the number of glial inclusions was low, ramified astrocytes and various forms of astrocytes with AT8-positive inclusions were also found. Thus, the case may reflect preclinical or very early clinical Pick disease. Distribution of PBs does not necessarily have to be consistent with previously reported preclinical/early clinical Pick disease. These results show that tau pathology in the earlier stage of Pick disease may be heterogeneous, and the anterior cingulate gyrus may be initially affected in Pick disease. Neuropathological examination, including immunohistochemistry without case selection, is useful in identifying clinical and pathological manifestations of Pick disease.


2018 ◽  
Author(s):  
Benjamin Falcon ◽  
Wenjuan Zhang ◽  
Alexey G. Murzin ◽  
Garib Murshudov ◽  
Holly J. Garringer ◽  
...  

The ordered assembly of tau protein into abnormal filamentous inclusions underlies many human neurodegenerative diseases1. Tau assemblies appear to spread through specific neural networks in each disease2, with short filaments having the greatest seeding activity3. The abundance of tau inclusions strongly correlates with disease symptoms4. Six tau isoforms are expressed in normal adult human brain - three isoforms with four microtubule-binding repeats each (4R tau) and three isoforms lacking the second repeat (3R tau)1. In various diseases, tau filaments can be composed of either 3R tau or 4R tau, or of both 3R and 4R tau. They have distinct cellular and neuroanatomical distributions5, with morphological and biochemical differences suggesting that they may be able to adopt disease-specific molecular conformations6,7. Such conformers may give rise to different neuropathological phenotypes8,9, reminiscent of prion strains10. However, the underlying structures are not known. Using electron cryo-microscopy (cryo-EM), we recently reported the structures of tau filaments from Alzheimer’s disease, which contain both 3R and 4R tau11. Here we have determined the structures of tau filaments from Pick’s disease, a neurodegenerative disorder characterised by frontotemporal dementia. They consist of residues K254-F378 of 3R tau, which are folded differently when compared to tau in Alzheimer’s disease filaments, establishing the existence of conformers of assembled tau. The Pick fold explains the selective incorporation of 3R tau in Pick bodies and the differences in phosphorylation relative to the tau filaments of Alzheimer’s disease. Our findings show how tau can adopt distinct folds in human brain in different diseases, an essential step for understanding the formation and propagation of molecular conformers.


2013 ◽  
Vol 137 (3) ◽  
pp. 314-325 ◽  
Author(s):  
Eileen H. Bigio

Context.—Autopsy evaluation of the brain of a patient with frontotemporal dementia (FTD) can be daunting to the general pathologist. At some point in their training, most pathologists learn about Pick disease, and can recognize Pick bodies, the morphologic hallmark of Pick disease. Pick disease is a type of frontotemporal lobar degeneration (FTLD), the general category of pathologic process underlying most cases of FTD. The 2 major categories of pathologic FTLD are tauopathies (FTLD-tau) and ubiquitinopathies (FTLD-U). Pick disease is one of the FTLD-tau subtypes and is termed FTLD-tau (PiD). Objective.—To “demystify” FTLDs, and to demonstrate that subtypes of FTLD-tau and FTLD-U can be easily determined by following a logical, stepwise, histochemical, and immunohistochemical investigation of the FTD autopsy brain. Data Sources.—Previously published peer-reviewed articles. Conclusions.—The hope is that this article will be a useful reference for the general pathologist faced with performing a brain autopsy on a decedent with frontotemporal dementia.


2013 ◽  
Vol 39 (2) ◽  
pp. 166-178 ◽  
Author(s):  
G. G. Kovacs ◽  
A. J. M. Rozemuller ◽  
J. C. van Swieten ◽  
E. Gelpi ◽  
K. Majtenyi ◽  
...  
Keyword(s):  

2012 ◽  
Vol 180 (4) ◽  
pp. 1394-1397 ◽  
Author(s):  
Miho Uematsu ◽  
Eijiro Adachi ◽  
Ayako Nakamura ◽  
Kuniaki Tsuchiya ◽  
Toshiki Uchihara
Keyword(s):  

Author(s):  
Lars Gustafson ◽  
Arne Brun

Nosological classification of organic dementia is based on current knowledge and theories of aetiology, including genetics, clinical picture, the pathological substrate, and the predominant location of brain damage. This chapter is concerned with dementia syndromes caused by a degenerative disease primarily affecting the frontal and temporal lobes, named frontal-lobe dementia or frontotemporal dementia (FTD). The terminology should be viewed from a historical perspective. The relationship between localized cortical atrophy in dementia and symptoms of aphasia was first reported by Pick in 1892. The pathological account of this lobar degeneration by Alzheimer in 1911 described ‘ballooned’ neurones (Pick cells) and argentophilic globes (Pick bodies), and the clinicopathological entity was named Pick's disease. In the 1980s, attention was drawn to a larger group of frontal-lobe dementias associated with frontotemporal cortical degeneration. The Lund–Manchester consensus of 1994 delineated the prototypical clinical syndrome of FTD with three neuropathological constituents, frontal lobe degeneration of non-Alzheimer type (FLD), (alternatively designated ‘dementia lacking distinctive histology’), Pick's disease, and motor neurone disease (MND) with dementia (FTD-MND). The 1998 consensus on clinical diagnostic criteria for frontotemporal lobar degeneration (FTLD) encompassed two additional dementia syndromes; progressive non-fluent aphasia (PA), and semantic dementia. Corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) have also been associated with FTLD. A changing clinical classification is shown in Fig. 4.1.3.1. The addition of important genetic and histochemical characteristics has further added to the complex classification of FTD and FTLD with a risk of developing numerous and partly competing definitions. FTLD may be further subclassified into forms positive or negative for tau and ubiquitin. The ubiquitinated form will be referred to as FTD-U, which is synonymous to FLTD-U.


Sign in / Sign up

Export Citation Format

Share Document